CPA
PTCT icon

Capital Performance Advisors’s PTC Therapeutics PTCT Stock Holding History

Capital Performance Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-373
Closed -$13.8K – 2052
2024
Q3 		$13.8K Buy
+373
New +$12.5K ﹤0.01% 710

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Performance Advisors's PTCT Position: Q4 2024 in Review

Capital Performance Advisors sold out of PTC Therapeutics (PTCT) in Q4 2024, closing a stake of 373 shares — an estimated $13.8K sold.

Capital Performance Advisors first reported a position in PTCT in Q3 2024 and held it in 1 quarter. The position peaked at $13.8K in Q3 2024. 239 funds tracked by Wall St. Rank hold PTCT as of Q4 2024.

  • Capital Performance Advisors reported no remaining PTC Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 373 PTC Therapeutics shares in Q4 2024, an estimated $13.8K.
  • Capital Performance Advisors first reported a position in PTC Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's PTC Therapeutics position peaked at $13.8K in Q3 2024.
  • 239 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.